The effects of nanocurcumin supplementation on inflammation in hemodialysis patients: A randomized controlled trial.
Gene expression
IL-6
PBMC
TNF-α
hemodialysis
nanocurcumin
Journal
Hemodialysis international. International Symposium on Home Hemodialysis
ISSN: 1542-4758
Titre abrégé: Hemodial Int
Pays: Canada
ID NLM: 101093910
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
24
11
2020
received:
02
07
2020
accepted:
14
01
2021
pubmed:
10
2
2021
medline:
16
10
2021
entrez:
9
2
2021
Statut:
ppublish
Résumé
Serum levels of several pro-inflammatory cytokines are higher in hemodialysis patients compared to healthy people. Curcumin has been shown to be able to decrease cytokines levels in nonuremic subjects. Our goal was to evaluate the effect of nanocurcumin administration on cytokines levels in hemodialysis patients. The study was performed over a 3 months period on 54 hemodialysis patients who had been randomized to receive either nanocurcumin or placebo. Serum levels and gene expressions of tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6) were evaluated using enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (RT-PCR). Serum levels of IL-6 and TNF-α were similar in the two groups at baseline but were lower after 12 weeks of treatment with nanocurcumin compared to placebo (P = 0.024 for IL-6 and 0.02 for TNF). In the group given nanocurcumin, serum levels of both cytokines decreased substantially (P < 0.001 for each), whereas they were unchanged in the group given placebo. Gene expression for each cytokine in peripheral blood mononuclear cells (PBMCs) was reduced at 12 weeks vs. baseline in the group given nanocurcumin, and changes in gene expression correlated with changes in serum level for each of the two cytokines. The results indicate that nanocurcumin supplementation reduces both serum levels and gene expression of IL-6 and TNF-α in hemodialysis patients. The feasibility and potential clinical benefits of nanocurcumin treatment to reduce inflammation in hemodialysis patients warrant further study.
Substances chimiques
Cytokines
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
232-239Informations de copyright
© 2021 International Society for Hemodialysis.
Références
Abreu CC, Cardozo L, Stockler-Pinto MB, et al. Does resistance exercise performed during dialysis modulate Nrf2 and NF-kappaB in patients with chronic kidney disease? Life Sci. 2017;188:192-197.
Alwahaibi N, Alissaei H, Al-Kalbani A, Alabri N, Allawati Z, Albalooshi M. Evaluation of interleukin-2, interleukin-8, and tumor necrosis factor-like weak inducer of apoptosis in hemodialysis and renal transplant patients and healthy controls. Saudi J Kidney Dis Transpl. 2016;27:1123-1128.
Babaei M, Dashti N, Lamei N, et al. Evaluation of plasma concentrations of homocysteine, IL-6, TNF-alpha, hs-CRP, and total antioxidant capacity in patients with end-stage renal failure. Acta Med Iran. 2014;52:893-898.
Oncel M, Akbulut S, Toka Ozer T, et al. Cytokines, adipocytokines and inflammatory markers in patients on continuous ambulatory peritoneal dialysis and hemodialysis. Ren Fail. 2016;38:1071-1075.
Khalatbari-Soltani S, Tabibi H. Inflammation and L-carnitine therapy in hemodialysis patients: A review. Clin Exp Nephrol. 2015;19:331-335.
Mirfatahi M, Tabibi H, Nasrollahi A, Hedayati M, Taghizadeh M. Effect of flaxseed oil on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients: A randomized controlled trial. Int Urol Nephrol. 2016;48:1335-1341.
Trivedi MK, Gangwar M, Mondal SC, Jana S. Role of vital trace elements in Nanocurcumin-centered formulation: A novel approach to resuscitate the immune system. Biol Trace Elem Res. 2018;182:265-277.
Hewlings SJ, Kalman DS. Curcumin: A review of Its' effects on human health. Foods (Basel, Switzerland). 2017;6:92.
de Almeida Alvarenga L, de Oliveira Leal V, Borges NA, et al. Curcumin-a promising nutritional strategy for chronic kidney disease patients. J Funct Foods. 2018;40:715-721.
Yallapu MM, Nagesh PKB, Jaggi M, Chauhan SC. Therapeutic applications of curcumin nanoformulations. AAPS J. 2015;17:1341-1356.
Strimpakos AS, Sharma RA. Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10:511-545.
Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets. 2011;12:332-347.
Dende C, Meena J, Nagarajan P, Nagaraj VA, Panda AK, Padmanaban G. Nanocurcumin is superior to native curcumin in preventing degenerative changes in experimental cerebral malaria. Sci Rep. 2017;7:10062.
Hatamipour M, Sahebkar AH, Alavizadeh SH, Dorri M, MRJIJoBMS J. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. IJBMS. 2019;22:282-289.
Rahimnia AR, Panahi Y, Alishiri G, Sharafi M, Sahebkar A. Impact of supplementation with Curcuminoids on systemic inflammation in patients with knee osteoarthritis: Findings from a randomized double-blind placebo-controlled trial. Drug Res (Stuttg). 2015;65:521-525.
Samadian F, Dalili N, Poor-Reza Gholi F, et al. Evaluation of Curcumin's effect on inflammation in hemodialysis patients. Clin Nutr ESPEN. 2017;22:19-23.
Zyga S, Kolovos P. Cardiovascular disease and chronic inflammation in end stage kidney disease. Int J Caring Sci. 2013;6:29-36.
Assa S, Hummel YM, Voors AA, et al. Hemodialysis-induced regional left ventricular systolic dysfunction and inflammation: A cross-sectional study. Am J Kidney Dis. 2014;64:265-273.
Panahi Y, Hosseini MS, Khalili N, et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharmacother. 2016;82:578-582.
O'Rourke RW, Kay T, Lyle EA, et al. Alterations in peripheral blood lymphocyte cytokine expression in obesity. Clin Exp Immunol. 2006;146:39-46.
Lin H, Joehanes R, Pilling LC, et al. Whole blood gene expression and interleukin-6 levels. Genomics. 2014;104:490-495.
Marti A, Morell-Azanza L, Rendo-Urteaga T, et al. Serum and gene expression levels of CT-1, IL-6, and TNF-α after a lifestyle intervention in obese children. Pediatr Diabetes. 2018;19:217-222.
Takahashi T, Kubota M, Nakamura T, Ebihara I, Koide H. Interleukin-6 gene expression in peripheral blood mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail. 2000;22:345-354.
Navarro-Gonzalez J, Mora-Fernandez C, Gomez-Chinchon M, Muros M, Herrera H, Garcia J. Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: Effect of amlodipine administration. Int J Immunopathol Pharmacol. 2010;23:51-59.
Di Nicola M, Cattaneo A, Hepgul N, et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun. 2013;31:90-95.
Guo Y, Xiao P, Lei S, et al. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai). 2008;40:426-436.
Moreillon JJ, Bowden RG, Deike E, , , et al. The use of an anti-inflammatory supplement in patients with chronic kidney disease. J Complement Integr Med. 2013;10:143-152.
Sun X, Liu Y, Li C, et al. Recent advances of curcumin in the prevention and treatment of renal fibrosis. Biomed Res Int. 2017;2017:1-9.
Abdolahi M, Tafakhori A, Togha M, et al. The synergistic effects of omega-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-alpha gene expression and serum level in migraine patients. Immunogenetics. 2017;69:371-378.
Cohen SD, Phillips TM, Khetpal P, Kimmel PL. Cytokine patterns and survival in haemodialysis patients. Nephrol Dial Transplant. 2010;25:1239-1243.
Pedruzzi LM, Cardozo LF, Daleprane JB, et al. Systemic inflammation and oxidative stress in hemodialysis patients are associated with down-regulation of Nrf2. J Nephrol. 2015;28:495-501.